Evidence map›Paper›PMID 31902358›Full record

ReviewMini reviews in medicinal chemistry2020

Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance.

Kajal Ghosal, Christian Agatemor, Richard I Han, Amy T Ku, Sabu Thomas, Sudit Mukherjee

Open access · greenAbstract readReview
In one paragraph

Review in Mini reviews in medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Kajal GhosalDr. B.C. Roy College of Pharmacy and AHS, Durgapur 713206, India.
Christian AgatemorDepartment of Biomedical Engineering, School of Medicine, John Hopkins University, Baltimore MD, 21231, United States.
Richard I HanDepartment of Bioengineering, Rice University, Houston TX, 77030, United States.
Amy T KuLester and Sue Smith Breast Center, Baylor College of Medicine, Houston TX, 77030, United States.
Sabu ThomasInternational and Inter University Center for Nanoscience and Nanotechnology (IIUCNN), Mahatma Gandhi University, Priyadarshini Hill, Kottayam 686560, Kerala, India.
Sudit MukherjeeDeparment of Biotechnology, National Institute of Technology, Durgapur, India.
Baylor College of Medicine · USJohns Hopkins University · USMahatma Gandhi University · INNational Institute of Technology Durgapur · INRice University · US

Funding

Translational Breast Cancer Research Training ProgramT32CA203690 · NCI · BAYLOR COLLEGE OF MEDICINE · PI FUQUA, SUZANNE AW, RIMAWI, MOTHAFFAR FAHED · 2018 to 2022
$1.0M
NCI NIH HHS T32 CA203690
6 · The paper itself

Abstract

Chemotherapy employs anti-cancer drugs to stop the growth of cancerous cells, but one common obstacle to the success is the development of chemoresistance, which leads to failure of the previously effective anti-cancer drugs. Resistance arises from different mechanistic pathways, and in this critical review, we focus on the Fanconi Anemia (FA) pathway in chemoresistance. This pathway has yet to be intensively researched by mainstream cancer researchers. This review aims to inspire a new thrust toward the contribution of the FA pathway to drug resistance in cancer. We believe an indepth understanding of this pathway will open new frontiers to effectively treat drug-resistant cancer.

Indexed as

DNA RepairDrug Resistance, NeoplasmAntineoplastic AgentsBiomarkersFanconi Anemia Complementation Group ProteinsHumansNeoplasmsSignal TransductionSmall Molecule LibrariesAntineoplastic AgentsBiomarkersFanconi Anemia Complementation Group ProteinsSmall Molecule LibrariesAlternative treatmentAnti-cancer drugsChemo-resistant cancer cellsChemotherapyDNAFanconi anaemia pathway.

Identifiers

PMID31902358
PMCPMC9484032
OpenAlexW2997674317

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.